ResMed price target lowered to $180 from $255 at Mizuho

Mizuho lowered the firm’s price target on ResMed to $180 from $255 and keeps a Buy rating on the shares after meeting with management. The analyst cites heightened GLP-1 risk perception for the target drop. However, with ResMed stock discounted versus its recent valuation, the firm sees value considering the opportunity for growth despite GLP-1s.